Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652181 · ClinicalTrials.gov registry record
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 123
- Enrollment target
NCT03652181: Completed study, sponsored by University of Chicago.
NCT03652181 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 123 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03652181 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 123 participants
- Enrollment target
Study Summary
Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.
Primary Outcome
Number of new bleeds reported during the two year follow-up period in the cohort with CASH. We will assess the change in the number of new symptomatic hemorrhage from baseline to year 1 and year 1 to year 2 follow-up.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2022-11-03 |
What the finished NCT03652181 record still lists
NCT03652181 is an observational study that tracks outcomes without assigning an intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03652181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03652181 about?
NCT03652181 is a clinical study titled "CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness". Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, ...
What is the current status of trial NCT03652181?
This trial is currently completed. The enrollment target is 123 participants. The study started on 2018-08-20. Estimated completion is 2022-11-03.
Who is sponsoring clinical trial NCT03652181?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI